02/14/2017

Irinotecan ; SN-38

MORE NEWS

18/03/2024 12:36

Anapharm Bioanalytics Brazilian ANVISA Certificate Renewal

Anapharm Bioanalytics is proud to announce that it has recently renewed its ANVISA (Brazil) certification which is now valid until February 26th, 2026.

READ MORE
18/04/2023 16:38

Anapharm Bioanalytics Secures Funding from Eurostars and CDTI for Innovative Project on Therapy and Diagnosis of Ewing Sarcoma

Barcelona, April 18th, 2023 – Anapharm Bioanalytics, a leading bioanalytical contract research organization (CRO), is delighted to announce the successful acquisition of funding from the Eurostars-3 joint program, with co-funding from CDTI (Centre for Industrial Technological Development) and the European Union’s Horizon Europe Research and Innovation Framework. This funding marks a significant milestone for the groundbreaking project, a collaborative effort between Anapharm Bioanalytics, iCellate Medical, and Aptadel Therapeutics.

READ MORE
03/06/2022 12:39

Challenges in the Development of a Method for the Detection of Anti-PEGylated-aptamer Antibodies

Immunogenicity assays capable of properly determining the presence of anti-drug antibodies (ADA) and anti-PEG antibodies have been recognized of great importance due to the fact that pre-existing anti-PEG antibodies could have an impact on the efficacy of a drug coupled to polyethylene glycol (PEG).

READ MORE